New combo aims to control lung cancer when immunotherapy fails
NCT ID NCT03527108
First seen Jan 20, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This phase 2 trial is testing whether combining two drugs—nivolumab and ramucirumab—can help control advanced non-small cell lung cancer in people who have already tried immunotherapy. The study will enroll 36 participants and measure how many achieve stable disease or tumor shrinkage. The goal is to see if this combination can offer a new option when standard treatments stop working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
NYU Langone
New York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ramucirumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has progressed after prior immunotherapy.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The combination may cause side effects like fatigue, high blood pressure, or immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.